H.C. Wainwright reiterates Korro Bio stock rating on trial dosing
H.C. Wainwright reiterated a Buy rating and $15.00 price target for Korro Bio (KRRO) after the company dosed the first cohort in its Phase 1/2 trial for KRRO-121. The stock is down 77% over the past year, trading at $9.97. Korro Bio has a strong current ratio of 9.55 and more cash than debt. The ANCHOR trial is expected to take about a year, with primary completion estimated for the second half of 2027.
How this was made
The 30-second read
Why it matters
The dosing of the first cohort marks the first in‑human exposure, a key milestone that can shift valuation.
Market read
The news is a primary biotech catalyst that may drive short‑term price movement for KRRO.
What to watch
Funding runway and competition from other hyperammonemia therapies may limit upside.
Background
Korro Bio (KRRO) is a micro‑cap biotech developing RNA‑editing therapy KRRO-121 for hyperammonemia. Analyst coverage has been positive, with price targets of $15 and $23.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $15 price target after Korro Bio dosed the first cohort in its Phase 1/2 trial for KRRO-121.
likely upside as investors price in progress of the KRRO-121 trial
Trial dosing is a primary disclosure for a biotech; market typically reacts positively to forward‑looking clinical milestones.
Market effects
Positive data could boost sentiment in the rare‑disease biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If early safety signals are ambiguous, the stock could face pressure despite the trial start.
Key entities
- companyKorro Bio Inc.
Developer of KRRO-121, listed on NASDAQ.
- analystH.C. Wainwright
Reiterated Buy rating and $15 price target.
